Peri-operative immunoadsorption in sensitized renal transplant recipients

Size: px
Start display at page:

Download "Peri-operative immunoadsorption in sensitized renal transplant recipients"

Transcription

1 Nephrol Dial Transplant (2002) 17: Original Article Peri-operative immunoadsorption in sensitized renal transplant recipients Martin Haas 1, Georg A. Böhmig 1, Zdenka Leko-Mohr 1, Markus Exner 2, Heinz Regele 3, Kurt Derfler 1, Walter H. Hörl 1 and Wilfred Druml 1 1 Division of Nephrology and Dialysis, Department of Internal Medicine III, University of Vienna, Austria, 2 Department of Laboratory Medicine, University of Vienna, Austria and 3 Division of Ultrastructural Pathology and Cell Biology, Department of Pathology, University of Vienna, Austria Abstract Background. Re-transplanted kidney allograft recipients with high levels of panel reactive antibodies (PRA) are at increased risk of early immunologic graft loss. In these patients, prophylactic peri-operative antibody depletion by immunoadsorption (IA) could prevent humoral graft injury and thus, in combination with anti-cellular rejection therapy, improve graft survival. Methods. Twenty re-transplanted and broadly immunized cadaver kidney recipients (median PRA reactivity 87%, range %) were treated with IA (protein A) immediately before transplantation and during the early post-transplantation period (median number of IA sessions 11, range 1 24). Patients received additional prophylactic anti-lymphocyte antibody therapy. Nineteen patients had a negative pre-transplant crossmatch. In one patient, a positive cross-match was rendered negative by the pre-transplant IA session. Results. One-year graft survival was 80% and patient survival 95%. Median (range) serum creatinine in functioning grafts was 1.6 ( ) mgudl at discharge and 1.5 ( ) mgudl at 1 year. Two grafts were lost due to acute vascular rejection, whereby one rejection occurred after withdrawal of immunosuppression due to septicaemia. One patient had acute cellular rejection, which was reversed by a second course of anti-lymphocyte antibody therapy. Thrombotic microangiopathy and surgical complications were the causes for one graft loss each. Retrospective immunohistochemistry revealed peritubular C4d staining, a presumed marker for humoral alloreactivity, in 12 out of 15 biopsies. Conclusions. These results suggest that prophylactic peri-operative IA and anti-lymphocyte antibody therapy might be an effective therapeutic strategy Correspondence and offprint requests to: Martin Haas, MD, Division of Nephrology and Dialysis, Department of Internal Medicine III, University of Vienna, Währinger Guertel 18 20, A-1090 Vienna, Austria. martin.haas@akh-wien.ac.at for the prevention of early graft failure in sensitized re-transplant recipients. Keywords: HLA-antibodies; humoral response; hypersensitized patients; immunoadsorption; kidney re-transplant; kidney transplantation; renal graft rejection Introduction Broadly immunized re-transplant recipients represent a growing group on the transplant waiting list. Besides the high probability of a positive pre-transplant cytotoxic cross-match, episodes of acute rejections in sensitized patients are frequent and transplant survival is below that observed in non-sensitized recipients [1 3]. Optimal immunosuppressive therapy for highly immunized transplant recipients remains undefined. As a means to improve graft survival, administration of mono- or polyclonal anti-lymphocyte antibodies as part of a quadruple induction therapy has been recommended [4 11]. Still, despite reduction of cellular rejections in these patients, a high incidence of early graft failure was reported [4 8,10 11]. An increasing number of studies emphasize the important pathogenetic role of alloantibodies, which can have a detrimental influence on graft survival [12 18]. Particularly broadly sensitized recipients are susceptible to humoral graft injury [12,13,15,16,18]. On this basis we hypothesized that a more efficient prophylaxis against acute rejection in sensitized patients might be achieved by targeting not only cellular but also humoral immune responses. Extracorporeal immunoadsorption (IA) is considered to be the most efficient way to remove antibodies. A single treatment session is able to decrease IgG levels by 80% [19]. IA has thus been used to effectively # 2002 European Renal Association European Dialysis and Transplant Association

2 1504 M. Haas et al. Table 1. Individual parameters and outcome of 20 broadly sensitized transplant recipients treated with quadruple immunosuppresive therapy and peri-operative IA Patient no. Age (years) Sex Tx no. CIT (h) MM C4d Graft biopsies (days after Tx) DGF Cr (discharge) (mgudl) Cr (1 year) (mgudl) 1 50 m positive BL (11) yes m positive NH, BL, BII (5, 16, 27) yes m nobx nobx no m positive BL, BII, NH, BL (16, 21, 43, 76) non-function HD HD 5 36 m positive ATN, TMA (5, 10) non-function HD HD 6 46 m positive ATN, BII (6, 90) yes died 7 34 m positive ATN (5) yes f positive ATN (1) yes m nobx nobx yes m nobx nobx no f positive TMA (9) no m positive ATN (2) yes m negative RVT with ATN (1) non-function HD HD m positive ATN (5) yes m nobx nobx no m positive ATN, NH, NH (7, 21, 40) yes m positive ATN (8) yes f negative ATN (9) yes m negative NH (11) no m nobx nobx no Tx, number of transplantations; CIT, cold ischaemic time; MM, mismatch; DGF, delayed graft function; Cr, creatinine; nobx, no biopsy; BL, borderline rejection; BII, Banff II rejection; NH, normal histology; TMA, thrombotic microangiopathy; ATN, acute tubular necrosis; RVT, renal vein thrombosis. reverse acute humoral rejection in refractory patients [20 24], which is why we hypothesized that prophylactic IA therapy might be equally efficient in broadly sensitized patients prone to antibody-mediated graft loss. Subjects and methods Patients Between the years 1995 and 2000, 20 broadly sensitized (panel reactive antibodies (PRA) greater than 50%) retransplanted cadaveric renal allograft recipients were treated with IA immediately before and after transplantation. Demographic data are listed in Table 1. The median (range) of previous graft survival was 3 (0.1 10) years, and less than 4 years in 16 out of 20 patients. All transplantations were performed within the Eurotransplant region and both donors and recipients were Caucasians. The median donor age was 36.6 (2 66) years and median recipient age 46.5 (20 71) years. Thirteen recipients underwent a second, five a third, and two a fifth kidney transplant. Included patients had been on the transplant waiting list for a median of 30 (8 131) months. According to the rules of Eurotransplant, all patients had a negative historic cytotoxic cross-match. The current cytotoxic cross-match (prior to initiation of IA) was negative in 19 out of 20 recipients. In one patient, a positive pre-ia cross-match was rendered negative by a 3 h course of IA. Immunological techniques Cytotoxic cross-match testing was performed with donor peripheral blood mononuclear cells according to the rules of the Eurotransplant Organization using the standard microcytotoxicity technique described by Terasaki and McClelland [25]. Cytotoxic PRA reactivity was assessed using a panel of cells from 20 to 50 phenotyped donors. For exclusion of IgM, tested sera were pre-treated with dithiotreitol. Immunosuppression The procedure of IA is reported elsewhere in detail [26]. Briefly, the patients underwent plasma separation using the autopheresis-ctm therapeutic plasma system (Baxter, IL). During each session, 2.5 plasma volumes were run alternatively over two cartridges containing staphylococcal protein A (Excorim, Lund, Sweden). For removal of bound immunoglobulin, the column was flushed with sodium citrate after each cycle and for storage with phosphate-buffered saline and 0.9% NaCl solution. IA was initiated and performed once immediately before renal transplantation and then every 2 3 days until stabilization of graft function (serum creatinine less than 2 mgudl) or graft loss. The number of sessions ranged between 1 and 24 (median 11), since the time to graft function differed. Total serum IgG levels were effectively reduced by IA in all patients and were below the detectable level after the last IA session (less than 1.95 gul) in most of them (Table 2). As assessed in 16 out of 20 patients, PRA levels, determined simultaneously with the IgG levels, were significantly reduced upon IA treatment (87%, range % before vs 53%, range % after IA; P-0.001). The median PRA titre of 14 out of 20 patients decreased from 1 : 32 (1 : 2 1 : 32) to 1 : 3 (1 : 2 1 : 8) (Table 2). The basal immunosuppressive therapy consisted of cyclosporine (adjusted to trough levels between 200 and 250 nguml for the early post-transplant period (8 weeks) and then reduced to nguml), steroids (according to a local tapering regimen), and mycophenolate mofetil at 2 guday (dose-adjusted according to white blood cells). Nineteen patients received prophylactic therapy with anti-lymphocyte

3 Apheresis in sensitized graft recipients Table 2. PRA concentration and titre, and serum IgG level before the first (1) and after the last (2) IA-session 1505 Patient no. PRA 1 (%) PRA 2 (%) Titre 1 Titre 2 IgG 1 (gul) IgG 2 (gul) IA total sessions : 16 1 : :32 1: n.d. n.d. n.d n.d. n.d :32 1: n.d. n.d. n.d n.d. n.d. n.d : 8 1 : n.d. n.d. n.d : 32 1 : : 32 1 : : 8 1 : : 16 1 : : 32 1 : n.d. n.d : 32 1 : : 32 1 : : 32 1 : : 2 1 : : 32 1 : n.d., not done. antibody (rabbit, or horse, anti-lymphocyte serum (ALS); initial dose 5 10 mgukguday; Pasteur Merieux S.V., France) for a treatment course of days. The dose was adjusted according to the white blood cell count. To minimize reduction of ALS levels by IA as a result of antibody binding to staphylococcal protein A, anti-lymphocyte antibody was infused shortly after each IA treatment session. One patient (no. 16) with a history of allergic reactions towards mono- (OKT3) and polyclonal anti-lymphocyte antibodies received prophylactic anti-il-2r antibody (20 mg at transplantation and after 5 days; basiliximab (Simulect 1 ), Novartis, NJ, USA). Ganciclovir (tapered according to renal function) was administered to all patients as prophylaxis against CMV infection. Anti-cellular rejection therapy consisted of high-dose steroids (dexamethasone, 100 mguday for 3 days) with or without an additional course of poly- or monoclonal anti-lymphocyte antibody. Three patients were converted from cyclosporine to tacrolimus, in one case because of severe rejection, in the other two cases because of suspected cyclosporine-induced haemolytic uraemic syndrome (HUS). Renal allograft biopsy Percutaneous renal biopsy was performed in 15 patients (three with initial non-function and 12 with delayed graft function). For histopathological analysis, paraffin-embedded sections were stained with haematoxylin and eosin, Periodic Acid-Schiff, Methenamin-Silver and with the trichrome stain Acidic Fuchsin-Orange-G. The histopathological classification was done according to the Banff Working Classification of Kidney Transplant Pathology [30]. C4d staining on paraffin-embedded sections was made according to a protocol described previously [18]. Statistical analysis All results are expressed as mean"sd or median and range when appropriate. A two-tailed Student s t-test for paired data was used to assess differences between two time points within the group. A P value was considered to indicate statistical significance. Results Clinical outcome Clinical data and biopsy results are given in Table 1. In the 20 highly sensitized re-transplant recipients subjected to prophylactic IA treatment, 1-year graft survival was 80%, and patient survival was 95% (Figure 1). Median (range) serum creatinine in functioning grafts (ns16) was 1.6 ( ) mgudl at discharge and 1.5 ( ) mgudl after 1 year. Eleven recipients (55%) had delayed graft function (DGF) and needed initial haemodialysis for at least 1 week (mean"sd, number of dialysis sessions 8"3). One of these patients (no. 2) showed acute vascular rejection (Banff IIA) in a biopsy performed 4 weeks after transplantation. In two previous biopsy specimens of the same patient, no signs of acute rejection were found. Graft function improved upon steroid bolus therapy and a second course of anti-lymphocyte antibody. In one recipient with DGF (no. 9) initial non-function of the graft was suspected to be due to allograft rejection, but wound infection prevented kidney biopsy. However, high-dose steroids and tacrolimus rescue therapy were given whereon kidney function recovered. A third patient with DGF (no. 11) showed histologic signs of thrombotic microangiopathy in a biopsy performed 9 days after transplantation. Based on laboratory evaluation (thrombocytopenia, substantial increase of LDH levels and Coombsnegative haemolysis) cyclosporine-induced HUS was suspected. After conversion to tacrolimus and

4 1506 M. Haas et al. Fig. 1. One-year graft and patient survival in 20 broadly sensitized recipients treated with prophylactic IA and quadruple therapy. initiation of plasma exchange in addition to IA, renal function improved and the patient was discharged with excellent graft function. In eight recipients, early renal biopsy revealed acute tubular necrosis (ATN) as morphologic correlate of DGF. Graft function recovered in all patients without additional immunosuppression. One of these patients (no. 6), however, developed severe methicillin-resistant Staphylococcus aureus septicaemia 6 weeks after transplantation. Following stepwise withdrawal of basal immunosuppression, severe acute rejection (Banff IIA) occurred and made transplant nephrectomy necessary. About 1 week later, the patient died from sepsis and multisystem organ failure. Another three recipients lost their graft during the early post-transplantation period. One allograft (no. 13) was lost because of surgical complication (renal vein thrombosis) two days after transplantation. In another patient (no. 4) with graft loss, a first biopsy (day 16) performed because of initial nonfunction of the transplanted kidney revealed Banff borderline lesion. The presence of intracapillary granulocytes in this specimen pointed to humoral graft injury. In a subsequent biopsy (day 21), borderline changes had progressed to acute vascular rejection (Banff IIA), whereon monoclonal antibody therapy with OKT3 (5 mguday for 10 days) was initiated. Two subsequent biopsies revealed a complete remission of cellular rejection and disappearance of intracapillary granulocytes. Nevertheless, graft function did not recover and the patient remained on dialysis. The fourth graft loss occurred in a patient (no. 5) with an initially well functioning transplant. At day 5, severe graft dysfunction occurred together with thrombocytopenia and laboratory signs of haemolysis. This and the histologic finding of thrombotic microangiopathy (TMA) led to the diagnosis of cyclosporine-induced HUS. IA and cyclosporine were converted to plasma exchange and tacrolimus, however, graft function did not recover and the patient remained on haemodialysis. C4d staining C4d staining was performed in all 15 histologically examined patients (in 10 of them immunohistochemistry was done retrospectively). In 12 recipients (80%) at least one biopsy stained positive for C4d in PTC. In nine C4d-positive patients, biopsy revealed no unequivocal signs of cellular rejection (ATN, ns6; TMA, ns2; Banff borderline, ns1). The remaining three C4d-positive patients showed features of vascular rejection. Three recipients were C4d negative. One of them had renal vein thrombosis. In the other two patients biopsy revealed normal histology or ATN, respectively. All grafts lost, except the one with renal vein thrombosis, were C4d positive. Infectious complications With the exception of the patient dying from severe septicaemia, no severe infection episodes occurred. Two patients developed mild CMV infection. Both patients were successfully treated with i.v. ganciclovir. Urinary tract infection in five and bacteraemia in two patients responded well to antibiotic therapy. Discussion In our study, we report the first prophylactic immunosuppressive regimen in broadly sensitized re-transplanted kidney graft recipients targeted specifically at both cellular and humoral alloreactivity.

5 Apheresis in sensitized graft recipients Our reported 1-year graft survival of 80% compares favourably to the 60 70% graft survival of sensitized recipients shown by previous studies aimed mainly at inhibiting cellular rejection [4 8,10,11]. Schroeder et al. [10] described an early graft loss due to hyperacute or acute rejection in 22% of the sensitized recipients treated with prophylactic quadruple therapy, and a 1-year graft survival of only 70%. Apparently, different results were presented by Thibaudin et al. [9], who reported a high graft survival in patients with more than 5% PRA treated with prophylactic quadruple therapy, but the data cannot be extrapolated to broadly sensitized recipients. Despite the classification of their patients in different groups of sensitization, the authors did not specify the graft survival for each group. Thus, it remains unclear how many of the approximately 50% acute rejections in the broadly sensitized recipients led to graft failure [9]. Furthermore the majority of the patients were not retransplanted and thus probably less prone to graft failure than our population. In those reports describing the outcome in sensitized recipients receiving a second or subsequent graft, 1-year survival was reported to be even worse than in sensitized first transplants. In the study of Gaston et al. [4], 40% of the patients receiving a re-transplant, in the presence of a negative pre-transplant CDC-cross-match, lost the graft within 1 year. As quadruple therapy did not improve the outcome, it was concluded that induction therapy with ALS is without benefit in patients undergoing repetitive transplantation. The data are in accordance with our own experiences. Between the years 1993 and 1995 highly sensitized and re-transplanted patients at our transplant centre were regularly treated with prophylactic quadruple immunosuppressive therapy. The 1-year graft survival during this period was similarly only 60%. It could be argued that transplant outcomes have been improving as immunosuppressive strategies have been changing in the latter years. In fact, according to USRDS, 1-year graft survival for patients with a PRA greater than 30% was 84% in 1997 and that of repeat transplants 82%. However, transplant survival of patients with both risk factors, i.e. high PRA concentrations and re-transplantation, remains clearly below non sensitized recipients. The Eurotransplant Foundation reports a 1-year graft survival of 70% (95% CI 67 73) in 1045 sensitized (PRA greater than 50%) recipients receiving a second or subsequent graft during the years (Drs J. Smits and G. Persijn, Eurotransplant Foundation, personal communication). This outcome underlines the importance of alternative immunosuppressive strategies in sensitized re-transplant recipients. The remarkable low incidence of immunologic graft losses seems particularly unusual given that 80% of the patients had a positive C4d staining. The high sensitivity of C4d in the diagnosis of acute humoral rejection and the close correlation to donor-specific antibodies has only recently been confirmed [28,29]. Thus, graft survival in C4d-positive patients is 1507 markedly decreased and has been reported to be as low as 60% [30]. Even if an aggressive post-transplant anti-rejection therapy is applied, including mycophenolate mofetil, tacrolimus and plasmapheresis, graft survival has been increased to at most 70% [28]. Our results stand in clear contrast to the reported low transplant survival in patients with anti-donor antibodies. Although the number of C4d-positive biopsies was almost three times as high as usual [28,29], 83% of the C4d-positive grafts survived beyond 1 year. In only two patients immune-mediated graft loss occurred. In both of them graft loss was attributed to vascular rejection, occurring after the end of induction therapy. Our finding of positive C4d staining in these recipients, in one of them associated with an accumulation of granulocytes in peritubulary capillaries, points at a contribution of humoral immune mechanisms to graft failure. In a third recipient, the finding of thrombotic microangiopathy together with distinct laboratory features led to the diagnosis of cyclosporine-induced HUS. Retrospective analysis, however, revealed endothelial C4d deposits. Capillary microthrombi with or without C4d deposits have earlier been described to be associated with antibody-positive rejection [1,30,31]. Accordingly, thrombotic microangiopathy in this patient could also be interpreted as a sign of refractory humoral injury. The general paucity of additional histological features for acute rejection (i.e. interstitial inflammatory infiltrates, vasculitis, tubulitis, polymorphonuclear cells in the peritubulary capillaries) could be explained by prophylactic anti-cellular and antihumoral therapy, which might have mitigated the histological picture. ATN was a common biopsy finding in our patients and was often associated with capillary C4d deposits. Previously, we were able to demonstrate that C4d deposits in acute humoral rejection persist despite successful anti-rejection therapy with IA [24]. Hence, C4d-positive ATN without other features of humoral rejection might represent a discrete lesion of antibody-mediated graft injury. In these patients, the complete manifestation of humoral rejection might have been prevented by early anti-humoral therapy. Although IA is highly effective in removing immunoglobulins, other methods might prove to be similarly successful. Plasma exchange has been shown to effectively reverse humoral rejection [32] and might be a promising prophylactic regimen when combined with i.v. IgG [33]. In addition, administration of a specific anti-cd20 monoclonal antibody (rituximab) directed against B cells might hinder donor-specific antibody synthesis. So far, however, none of these treatments has been administered to a larger transplant population as prophylactic post-transplant therapy and their efficacy in this setting still needs to be ascertained. In conclusion, our data suggest a beneficial effect of prophylactic peri-operative IA and anti-lymphocyte antibody therapy on graft survival in broadly sensitized renal re-transplant recipients. Inhibition of both

6 1508 M. Haas et al. the humoral and cellular arm of the immune system might comprise an increased graft survival in this specific group of high-risk patients, however, a prospective and randomized trial is warranted to definitely answer this question. References 1. Baldwin III WM, Halloran PF. Clinical syndromes associated with antibody in allografts. In: Racusen LC, Solez K, Burdick JF, eds, Kidney Transplant Rejection. Marcel Dekker Inc., New York: 1998; Opelz G. Collaborative transplant study 10-year report. Transplant Proc 1992; 24: Cecka JM. The UNOS scientific renal transplant registry. Clin Transplant 1998; Gaston RS, Shroyer TW, Hudson SL et al. Renal retransplantation: the role of race, quadruple immunosupression, and the flow cytometry cross-match. Transplantation 1994; 57: Katznelson S, Cecka J. Immunosuppressive regimens and their effects on renal allograft outcome. In: Cecka J, Terasaki P, eds, Clinical Transplants UCLA Tissue Typing Laboratory, Los Angeles: 1997; Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Collaborative Transplant Study. Transplantation 1995; 60: Szczech LA, Feldman HI. Effect of anti-lymphocyte antibody induction therapy on renal allograft survival. Transplant Proc 1999; 31 [Suppl 3B]: S First MR. Immunologically high-risk recipient strategies. Transplant Proc 1999; 31: Thibaudin D, Alamartine E, de Filippis JP et al. Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant 1998; 13: Schroeder TJ, First MR, Mansour ME et al. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Am J Kidney Dis 1989; 14 [Suppl 2]: Maes BD, Vanrenterghem YF. Induction with polyclonal antibodies. Curr Opin Organ Transplant 1999; 4: Martin S, Dyer PA, Mallick NP et al. Posttransplant antidonor lymphocytotoxic antibody production in relation to graft outcome. Transplantation 1987; 44: Halloran PF, Wadgymar A, Ritchie S et al. The significance of the anti-class I response. I. Clinical and pathological features of anti-class I mediated rejection. Transplantation 1990; 49: Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anti-class I response. II. Clinical and pathological features of renal transplants with anti-class I-like antibody. Transplantation 1992; 53: Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation. Kidney Int 1996; 50: Lederer SR, Kluth-Pepper B, Schneeberger H et al. Impact of humoral alloreactivity early after transplantation on the longterm survival of renal allografts. Kidney Int 2001; 59: Crespo M, Pascual M, Tolkoff-Rubin N et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 2001; 71: Regele H, Exner M, Watschinger B et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001; 16: Matic G, Hofmann D, Winkler R et al. Removal of immunoglobulins by a protein A versus an antihuman immunoglobulin G-based system: evaluation of 602 sessions of extracorporeal immunoadsorption. Artif Organs 2000; 24: Persson NH, Bucin D, Ekberg H et al. Immunoadsorption in acute vascular rejection after renal transplantation. Transplant Proc 1995; 27: Pretagostini R, Berloco P, Poli L et al. Immunoadsorption with protein A in humoral rejection of kidney transplants. ASAIO J 1996; 42: M Hickstein H, Korten G, Bast R et al. Protein A immunoadsorption (IA) in renal transplantation patients with vascular rejection. Transfusion Sci 1998; 19: S Böhmig GA, Regele H, Säemann MD et al. The role of humoral immune reactions as target for antirejection therapy in recipients of a spousal-donor kidney graft. Am J Kidney Dis 2000; 35: Böhmig GA, Regele H, Exner M et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption. J Am Soc Nephrol 2001; 12: Terasaki PI, McClelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964; 204: Haas M, Godfrin Y, Oberbauer R et al. Plasma immunoadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 1998; 13: Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: Mauiyyedi S, Crespo M, Collins AB et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: Nickeleit V, Zeiler M, Gudat F et al. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13: Feucht HE, Schneeberger H, Hillebrand G et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: Collins AB, Schneeberger EE, Pascual MA et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: Pascual M, Saidman S, Tolkoff-Rubin N. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 66: Schweitzer EJ, Wilson JS, Fernandez-Vina M et al. A high panel-reactive antibody rescue protocol for crossmatch-positive live donor kidney transplants. Transplantation 2000; 70: Received for publication: Accepted in revised form:

Focal peritubular capillary C4d deposition in acute rejection

Focal peritubular capillary C4d deposition in acute rejection Nephrol Dial Transplant (2006) 21: 1382 1388 doi:10.1093/ndt/gfk028 Advance Access publication 5 January 2006 Original Article Focal peritubular capillary C4d deposition in acute rejection Alexander B.

More information

Research Article The Diagnostic Value of Transcription Factors T-bet/GATA3 Ratio in Predicting Antibody-Mediated Rejection

Research Article The Diagnostic Value of Transcription Factors T-bet/GATA3 Ratio in Predicting Antibody-Mediated Rejection Clinical and Developmental Immunology Volume 2013, Article ID 460316, 6 pages http://dx.doi.org/10.1155/2013/460316 Research Article The Diagnostic Value of Transcription Factors T-bet/GATA3 Ratio in Predicting

More information

HLA and Non-HLA Antibodies in Transplantation and their Management

HLA and Non-HLA Antibodies in Transplantation and their Management HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating

More information

Peritubular capillaries C4d deposits in renal allograft biopsies and anti HLA I/II alloantibodies screening Incidence and clinical importance

Peritubular capillaries C4d deposits in renal allograft biopsies and anti HLA I/II alloantibodies screening Incidence and clinical importance ORIGINAL ARTICLE Port J Nephrol Hypert 2008; 22(1): 37-42 Peritubular capillaries C4d deposits in renal allograft biopsies and anti HLA I/II alloantibodies screening Incidence and clinical importance Helena

More information

Transplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab

Transplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab ORIGINAL ARTICLE Advance Access publication 1 February 2010 Transplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab Ana Carina Ferreira 1, Sandra Brum 1, Vasco

More information

Posttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients

Posttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients Trends in Transplant. 2014;8:3-9 Gregor Bartel, Georg A. Böhmig: Alloantibodies and Graft Function Posttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients Gregor Bartel

More information

The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss

The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss http://www.kidney-international.org 2015 International Society of Nephrology see commentary on page 218 The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk

More information

Humoral Rejection of Organ Allografts

Humoral Rejection of Organ Allografts American Journal of Transplantation 2005; 5: 2611 2618 Blackwell Munksgaard Minireview Copyright C Blackwell Munksgaard 2005 doi: 10.1111/j.1600-6143.2005.01086.x Humoral Rejection of Organ Allografts

More information

Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies

Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific

More information

Immunopathology of T cell mediated rejection

Immunopathology of T cell mediated rejection Immunopathology of T cell mediated rejection Ibrahim Batal MD Columbia University College of Physicians & Surgeons New York, NY, USA Overview Pathophysiology and grading of TCMR TCMR is still a significant

More information

Review of Rituximab and renal transplantation. Dr.E Nemati. Professor of Nephrology

Review of Rituximab and renal transplantation. Dr.E Nemati. Professor of Nephrology Review of Rituximab and renal transplantation Dr.E Nemati Professor of Nephrology Introductio n Rituximab is a chimeric anti-cd20 monoclonal antibody. The CD20 antigen is a transmembrane nonglycosylated

More information

RENAL EVENING SPECIALTY CONFERENCE

RENAL EVENING SPECIALTY CONFERENCE RENAL EVENING SPECIALTY CONFERENCE Harsharan K. Singh, MD The University of North Carolina at Chapel Hill Disclosure of Relevant Financial Relationships No conflicts of interest to disclose. CLINICAL HISTORY

More information

Reduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival

Reduced graft function (with or without dialysis) vs immediate graft function a comparison of long-term renal allograft survival Nephrol Dial Transplant (2006) 21: 2270 2274 doi:10.1093/ndt/gfl103 Advance Access publication 22 May 2006 Original Article Reduced graft function (with or without dialysis) vs immediate graft function

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated

More information

Predicting Kidney Graft Failure by HLA Antibodies: a Prospective Trial

Predicting Kidney Graft Failure by HLA Antibodies: a Prospective Trial American Journal of Transplantation 2004; 4: 438 443 Blackwell Munksgaard Copyright C Blackwell Munksgaard 2004 doi: 10.1111/j.1600-6143.2004.00360.x Predicting Kidney Graft Failure by HLA Antibodies:

More information

Renal Pathology- Transplantation. Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic

Renal Pathology- Transplantation. Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic Renal Pathology- Transplantation Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic eva.honsova@ikem.cz Kidney has a limited number of tissue reactions by which the kidney

More information

ABO mismatched Renal Transplants

ABO mismatched Renal Transplants ABO mismatched Renal Transplants Nicos Kessaris Renal Transplant Surgeon St George s Hospital, London 7 th March 2012 Why? Protocol Risks Experience abroad Experience in UK Experience at St George s Conclusions

More information

Detection of the Complement Degradation Product C4d in Renal Allografts: Diagnostic and Therapeutic Implications

Detection of the Complement Degradation Product C4d in Renal Allografts: Diagnostic and Therapeutic Implications J Am Soc Nephrol 13: 242 251, 2002 Detection of the Complement Degradation Product C4d in Renal Allografts: Diagnostic and Therapeutic Implications VOLKER NICKELEIT,* MATTHIAS ZEILER,* FRED GUDAT,* GILBERT

More information

Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant

Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was

More information

Management of Rejection

Management of Rejection Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center

More information

The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials

The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials Carmen Lefaucheur 1 2 Banff 2015: Integration of HLA-Ab for improving

More information

Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function

Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi

More information

Kidney Transplant. November 4 th, 2016

Kidney Transplant. November 4 th, 2016 Kidney Transplant November 4 th, 2016 Brad West, MD, FACP Medical Director of Transplant Services, Memorial Medical Center Chairman Department of Nephrology, Springfield Clinic 1 Adjusted survival: 1993-1997

More information

Strategies for Desensitization

Strategies for Desensitization Strategies for Desensitization Olwyn Johnston MB, MRCPI, MD, MHSc BC Nephrology Day October 8 th 2010 Pre-transplant crossmatch (CMX) with donor lymphocytes has been standard of practice Positive CDC CXM

More information

The classification and treatment of antibody-mediated renal allograft injury: Where do we stand?

The classification and treatment of antibody-mediated renal allograft injury: Where do we stand? http://www.kidney-international.org 2007 International Society of Nephrology see original article on page 24 he classification and treatment of antibody-mediated renal allograft injury: Where do we stand?

More information

James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant

James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant James E. Cooper, M.D. Assistant Professor, University of Colorado at Denver Division of Renal Disease and Hypertension, Kidney and PancreasTransplant Program Has no real or apparent conflicts of interest

More information

Why so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation

Why so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation Why so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation Stephen J Tomlanovich MD Objectives of this Talk Define the sensitized patient Describe the scope of the problem for a

More information

Emerging Drug List EVEROLIMUS

Emerging Drug List EVEROLIMUS Generic (Trade Name): Manufacturer: Everolimus (Certican ) Novartis Pharmaceuticals NO. 57 MAY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence: For use with cyclosporine

More information

Since the first Banff meeting in 1991, the diagnosis and

Since the first Banff meeting in 1991, the diagnosis and CLINICAL AND TRANSLATIONAL RESEARCH Acute Cellular Rejection: Impact of Donor-Specific Antibodies and C4d Michelle Willicombe, 1,5 Candice Roufosse, 2 Paul Brookes, 3 Adam G. McLean 1, Jack Galliford,

More information

Nephrology Dialysis Transplantation

Nephrology Dialysis Transplantation Nephrol Dial Transplant (1999) 14: 394 399 Original Article Nephrology Dialysis Transplantation Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil Rudolf P.

More information

Blood Group Incompatible Renal Transplantation and Apheresis. Liz Wright Clinical Nurse Specialist Great Ormond Street Hospital NHS FT

Blood Group Incompatible Renal Transplantation and Apheresis. Liz Wright Clinical Nurse Specialist Great Ormond Street Hospital NHS FT Blood Group Incompatible Renal Transplantation and Apheresis Liz Wright Clinical Nurse Specialist Great Ormond Street Hospital NHS FT Background There is growing interest in transplantation across the

More information

Case Report. thymocyte globulin therapy. Treatment with plasmapheresis/intravenous ABSTRACT

Case Report. thymocyte globulin therapy. Treatment with plasmapheresis/intravenous ABSTRACT Case Report Rev Port Nefrol Hipert 2006; 20 (2): 131-135 Triple regimen with rituximab, plasmapheresis and intravenous immunoglobulin in the treatment of dialysis dependent acute humoral-mediated rejection

More information

Microcirculation Inflammation Associates With Outcome in Renal Transplant Patients With De Novo Donor-Specific Antibodies

Microcirculation Inflammation Associates With Outcome in Renal Transplant Patients With De Novo Donor-Specific Antibodies American Journal of Transplantation 2013; 13: 485 492 Wiley Periodicals Inc. Brief Communication C Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons

More information

Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents

Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents BUMC Proceedings 1999;12:110-112 Pharmacology notes Interleukin-2 receptor-blocking monoclonal antibodies: evaluation of 2 new agents CHERYLE GURK-TURNER, RPH Department of Pharmacy Services, BUMC wo mouse/human

More information

Impact of Subclinical Rejection on Transplantation

Impact of Subclinical Rejection on Transplantation Trends in Transplantation 2007;1:56-60 Impact of Subclinical Rejection on Transplantation David N. Rush for the Winnipeg Transplant Group Transplant Manitoba Adult Kidney Program, University of Manitoba,

More information

Pathological back-ground of renal transplant pathology and important mile-stones of the Banff classification

Pathological back-ground of renal transplant pathology and important mile-stones of the Banff classification Banff 1 Banff Pathological back-ground of renal transplant pathology and important mile-stones of the Banff classification Department of Nephrology, Japanese Red Cross Nagoya Daini Hospital Morozumi Kunio,

More information

Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation

Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery

More information

NAPRTCS Annual Transplant Report

NAPRTCS Annual Transplant Report North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section

More information

ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies

ABO blood group-incompatible living donor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies Nephrol Dial Transplant (2009) 24: 298 303 doi: 10.1093/ndt/gfn478 Advance Access publication 26 August 2008 Original Article ABO blood group-incompatible living donor kidney transplantation: a prospective,

More information

The New England Journal of Medicine

The New England Journal of Medicine The New England Journal of Medicine Copyright, 2, by the Massachusetts Medical Society VOLUME 342 M ARCH 2, 2 NUMBER 9 IMPROVED GRAFT SURVIVAL AFTER RENAL TRANSPLANTATION IN THE UNITED STATES, 1988 TO

More information

The Banff Classification for Diagnosis of Renal Allograft Rejection: Updates from the 2017 Banff Conference

The Banff Classification for Diagnosis of Renal Allograft Rejection: Updates from the 2017 Banff Conference The Banff Classification for Diagnosis of Renal Allograft Rejection: Updates from the 2017 Banff Conference Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA Statement of Disclosure Mark

More information

NAPRTCS Annual Transplant Report

NAPRTCS Annual Transplant Report North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II

More information

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation Andreas Zuckermann, MD et al. Department of Cardio-Thoracic Surgery, Medical University

More information

Overview of New Approaches to Immunosuppression in Renal Transplantation

Overview of New Approaches to Immunosuppression in Renal Transplantation Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute

More information

Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome

Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome Pediatr Nephrol (2003) 18:833 837 DOI 10.1007/s00467-003-1175-4 BRIEF REPORT Gina-Marie Barletta William E. Smoyer Timothy E. Bunchman Joseph T. Flynn David B. Kershaw Use of mycophenolate mofetil in steroid-dependent

More information

Incidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review

Incidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review Incidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review Jessica Ludolph 1 Lynsey Biondi, MD 1,2 and Michael Moritz, MD 1,2 1 Department of Surgery,

More information

Should red cells be matched for transfusions to patients listed for renal transplantation?

Should red cells be matched for transfusions to patients listed for renal transplantation? Should red cells be matched for transfusions to patients listed for renal transplantation? Dr M.Willicombe Imperial College Renal and Transplant Centre, Hammersmith Hospital Should red cells be matched

More information

Diagnosis And Treatment Of Antibody Mediated Rejection Post Kidney And Kidney Pancreas Transplant RRCV CMG Renal and Transplant Service

Diagnosis And Treatment Of Antibody Mediated Rejection Post Kidney And Kidney Pancreas Transplant RRCV CMG Renal and Transplant Service Diagnosis And Treatment Of Antibody Mediated Rejection Post Kidney And Kidney Pancreas Transplant RRCV CMG Renal and Transplant Service 1. Introduction Transplantation offers better survival and quality

More information

Nephrology Grand Rounds

Nephrology Grand Rounds Nephrology Grand Rounds PTLD in Kidney Transplantation Charles Le University of Colorado 6/15/12 Objectives Background Pathogenesis Epidemiology and Clinical Manifestation Incidence Risk Factors CNS Lymphoma

More information

RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST

RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT J. H. Helderman,MD,FACP,FAST Vanderbilt University Medical Center Professor of Medicine, Pathology and Immunology Medical Director, Vanderbilt Transplant

More information

Desensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver

Desensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Desensitization in Kidney Transplant James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Organ Shortage Currently there are >90,000 patients on the kidney

More information

Kidney Transplantation

Kidney Transplantation Kidney Transplantation Current Kidney Transplantation Department of Surgery Yonsei University Wonju College of Medicine Kim Myoung Soo M.D. ysms91@wonju.yonsei.ac.kr http://gs.yonsei.ac.kr Current Kidney

More information

This study is currently recruiting participants.

This study is currently recruiting participants. A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting

More information

Clinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly Sensitized Renal Transplanted Patients

Clinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly Sensitized Renal Transplanted Patients BioMed Research International Volume 2013, Article ID 738404, 5 pages http://dx.doi.org/10.1155/2013/738404 Clinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly

More information

chapter 28 Manuel Muro, 1 Santiago Llorente, 2 Maria J. Gónzalez-Soriano, 2 Alfredo Minguela, 1 Luisa Gimeno, 2 and María R.

chapter 28 Manuel Muro, 1 Santiago Llorente, 2 Maria J. Gónzalez-Soriano, 2 Alfredo Minguela, 1 Luisa Gimeno, 2 and María R. chapter 28 Pre-formed Donor-Specific Alloantibodies (DSA) Detected Only by Luminex Technology Using HLA-Coated Microspheres and Causing Acute Humoral Rejection and Kidney Graft Dysfunction Manuel Muro,

More information

Acute renal failure (ARF) in the transplanted kidney represents a

Acute renal failure (ARF) in the transplanted kidney represents a Acute Renal Failure in the Transplanted Kidney Kim Solez Lorraine C. Racusen Acute renal failure (ARF) in the transplanted kidney represents a high-stakes area of nephrology and of transplantation practice.

More information

ABO. ABO ABO ABO ABO ABO ABO ABO ABO. Key words ABO. Alexandre ABO ABO. double filtration plasmapheresis, DFPP. antibody-mediated rejection, AMR

ABO. ABO ABO ABO ABO ABO ABO ABO ABO. Key words ABO. Alexandre ABO ABO. double filtration plasmapheresis, DFPP. antibody-mediated rejection, AMR ABO ABO ABO ABO ABO ABO ABO ABO ABO ABO.. ABO ABO. ABO. ABO ABO Key words ABO ABO A B antibody-mediated rejection, AMR Alexandre ABO double filtration plasmapheresis, DFPP ABO ABO n ABO n p-value R.....

More information

Statement of Disclosure

Statement of Disclosure Statement of Disclosure Mark Haas serves as a paid consultant on pathology adjudication committees for two industry-sponsored clinical trials: Shire ViroPharma Treatment of Acute ABMR AstraZeneca Treatment

More information

ABO-incompatible kidney transplantation in elderly patients over 60 years of age

ABO-incompatible kidney transplantation in elderly patients over 60 years of age Int Urol Nephrol (2012) 44:1563 1570 DOI 10.1007/s11255-012-0231-z NEPHROLOGY - ORIGINAL PAPER ABO-incompatible kidney transplantation in elderly patients over 60 years of age Junji Uchida Tomoaki Iwai

More information

XM-ONE XM-ONE XM-ONE. References XMO_V4.0_100205_CE.EU

XM-ONE XM-ONE XM-ONE.  References XMO_V4.0_100205_CE.EU Transplantation Cross match Transplantation Cross match XMO_V4._125_CE.EU Manufactured by: ABSORBER AB Address: Drottninggatan 33 SE-13 95 Stockholm, Sweden E-mail: info-ssp@olerup.com Tel: +46 8 5 89

More information

CASE REPORT ABSTRACT INTRODUCTION. Renal transplant was successfully performed after conversion.

CASE REPORT ABSTRACT INTRODUCTION. Renal transplant was successfully performed after conversion. CASE REPORT Port J Nephrol Hypert 2007; 21(1): 41-47 Successful live donor kidney transplant in a hypersensitised patient with positive cross-match. A case report and a review of the effectiveness of desensitisation

More information

Endothelitis in cardiac allograft biopsy specimens: Possible relationship to antibody-mediated rejection

Endothelitis in cardiac allograft biopsy specimens: Possible relationship to antibody-mediated rejection http://www.jhltonline.org ORIGINAL CLINICAL SCIENCE Endothelitis in cardiac allograft biopsy specimens: Possible relationship to antibody-mediated rejection Fabio Tavora, MD, a Raghava Munivenkatappa,

More information

Acute rejection and late renal transplant failure: Risk factors and prognosis

Acute rejection and late renal transplant failure: Risk factors and prognosis Nephrol Dial Transplant (2004) 19 [Suppl 3]: iii38 iii42 DOI: 10.1093/ndt/gfh1013 Acute rejection and late renal transplant failure: Risk factors and prognosis Luis M. Pallardo Mateu 1, Asuncio n Sancho

More information

Kidney Summary. Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA

Kidney Summary. Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA Kidney Summary Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA Key Issues to Address re: the Classification 1. Incorporation of i-ifta + tubulitis into the TCMR classification - Defining

More information

Ten-year survival of second kidney transplants: Impact of immunologic factors and renal function at 12 months

Ten-year survival of second kidney transplants: Impact of immunologic factors and renal function at 12 months Kidney International, Vol. 64 (2003), pp. 674 680 Ten-year survival of second kidney transplants: Impact of immunologic factors and renal function at 12 months STÉPHANIE COUPEL, MAGALI GIRAL-CLASSE, GEORGES

More information

Transplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes

Transplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes Transplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes INTRODUCTION In patients awaiting a transplant, having antibodies reactive to HLA antigens present

More information

Renal Data from the Arab World

Renal Data from the Arab World Saudi J Kidney Dis Transpl 2011;22(4):818-824 2011 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Renal Data from the Arab World Why does Kidney Allograft Fail?

More information

SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%

SELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80% SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney

More information

Case Presentation Turki Al-Hussain, MD

Case Presentation Turki Al-Hussain, MD Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory

More information

Clinical Study Over Ten-Year Kidney Graft Survival Determinants

Clinical Study Over Ten-Year Kidney Graft Survival Determinants International Nephrology Volume 2012, Article ID 302974, 5 pages doi:10.1155/2012/302974 Clinical Study Over Ten-Year Kidney Graft Survival Determinants Anabela Malho Guedes, 1, 2 Jorge Malheiro, 1 Isabel

More information

Biopsy Features of Kidney Allograft Rejection Banff B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary

Biopsy Features of Kidney Allograft Rejection Banff B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary Biopsy Features of Kidney Allograft Rejection Banff 2017 B. Ivanyi, MD Department of Pathology, University of Szeged, Szeged, Hungary Treatment of allograft dysfunction should rely on the biopsy findings

More information

Spectrum of complement-mediated thrombotic microangiopathies after kidney transplantation

Spectrum of complement-mediated thrombotic microangiopathies after kidney transplantation Spectrum of complement-mediated thrombotic microangiopathies after kidney transplantation Marius Miglinas Vilnius university hospital: Nephrology center, Center of Rare Kidney Diseases Vilnius university

More information

Antibody-Mediated Rejection in the Lung Allograft. Gerald J Berry, MD Dept of Pathology Stanford University Stanford, CA 94305

Antibody-Mediated Rejection in the Lung Allograft. Gerald J Berry, MD Dept of Pathology Stanford University Stanford, CA 94305 Antibody-Mediated Rejection in the Lung Allograft Gerald J Berry, MD Dept of Pathology Stanford University Stanford, CA 94305 Gerald J Berry, MD Professor of Pathology Stanford University, Stanford, CA

More information

Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab

Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab TRANSPLANTATION Recurrent Idiopathic Membranous Glomerulonephritis After Kidney Transplantation and Successful Treatment With Rituximab Khadijeh Makhdoomi, 1,2 Saeed Abkhiz, 1,2 Farahnaz Noroozinia, 1,3

More information

Antibody Mediated Rejection (AMR) in LUNG TRANSPLANT Recipients

Antibody Mediated Rejection (AMR) in LUNG TRANSPLANT Recipients Antibody Mediated Rejection (AMR) in LUNG TRANSPLANT Recipients Lorriana Leard, MD UCSF Transplant Pulmonologist Associate Professor of Clinical Medicine Vice Chief of Clinical Activities Pulmonary, Critical

More information

Pulmonary AMR Therapeutic Options & Strategies: The Old and the New. Ramsey Hachem, MD March 28, 2017

Pulmonary AMR Therapeutic Options & Strategies: The Old and the New. Ramsey Hachem, MD March 28, 2017 Pulmonary AMR Therapeutic Options & Strategies: The Old and the New Ramsey Hachem, MD March 28, 2017 Disclosures Ramsey Hachem I have no financial relations with any relevant commercial interests I will

More information

Rejection after simultaneous pancreas kidney transplantation

Rejection after simultaneous pancreas kidney transplantation Nephrol Dial Transplant (2005) 20 [Suppl 2]: ii11 ii17 doi:10.1093/ndt/gfh1077 Rejection after simultaneous pancreas kidney transplantation Helmut Arbogast 1, Jacques Malaise 3, Wolf-Dieter Illner 1, Anwar

More information

Renal transplantation in sensitized recipients with positive luminex and negative CDC (complement-dependent cytotoxicity) crossmatches

Renal transplantation in sensitized recipients with positive luminex and negative CDC (complement-dependent cytotoxicity) crossmatches Transplant International ISSN 0934-0874 ORIGINAL ARTICLE Renal transplantation in sensitized recipients with positive luminex and negative CDC (complement-dependent cytotoxicity) crossmatches Kyu Ha Huh,

More information

Posttransplant Prophylactic Intravenous Immunoglobulin in Kidney Transplant Patients at High Immunological Risk: A Pilot Study

Posttransplant Prophylactic Intravenous Immunoglobulin in Kidney Transplant Patients at High Immunological Risk: A Pilot Study American Journal of Transplantation 2007; 7: 1185 1192 Blackwell Munksgaard C 2007 The Authors Journal compilation C 2007 The American Society of Transplantation and the American Society of Transplant

More information

Renal Transplant. Tony Chacon. Program Head BCIT Nephrology Nursing Program.

Renal Transplant. Tony Chacon. Program Head BCIT Nephrology Nursing Program. Renal Transplant Tony Chacon Program Head BCIT Nephrology Nursing Program Email: tony_chacon@bcit.ca Summary of CNA Renal Transplant Competencies Potential contraindications to renal transplant. Assessment/selection

More information

Interstitial Inflammation

Interstitial Inflammation Interstitial Inflammation Currently considered to be T cell-mediated process Plasma cell rich acute rejection often associated with AMR Preliminary data suggests that interstitial follicular helper T cells

More information

3/6/2017. Prevention of Complement Activation and Antibody Development: Results from the Duet Trial

3/6/2017. Prevention of Complement Activation and Antibody Development: Results from the Duet Trial Prevention of Complement Activation and Antibody Development: Results from the Duet Trial Jignesh Patel MD PhD FACC FRCP Medical Director, Heart Transplant Cedars-Sinai Heart Institute Disclosures Name:

More information

Monoclonal Gammopathies and the Kidney. Tibor Nádasdy, MD The Ohio State University, Columbus, OH

Monoclonal Gammopathies and the Kidney. Tibor Nádasdy, MD The Ohio State University, Columbus, OH Monoclonal Gammopathies and the Kidney Tibor Nádasdy, MD The Ohio State University, Columbus, OH Monoclonal gammopathy of renal significance (MGRS) Biopsies at OSU (n=475) between 2007 and 2016 AL or AH

More information

Article. Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection

Article. Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection Article Capillary C4d and Kidney Allograft Outcome in Relation to Morphologic Lesions Suggestive of Antibody-Mediated Rejection Zeljko Kikic,* Alexander Kainz,* Nicolas Kozakowski, Rainer Oberbauer,* Heinz

More information

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent

More information

DE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY

DE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY 2016 DE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY James H Lan, MD, FRCP(C), D(ABHI) Clinical Assistant Professor, University of British Columbia Nephrology & Kidney Transplantation, Vancouver General

More information

Long-term prognosis of BK virus-associated nephropathy in kidney transplant recipients

Long-term prognosis of BK virus-associated nephropathy in kidney transplant recipients Original Article Kidney Res Clin Pract 37:167-173, 2018(2) pissn: 2211-9132 eissn: 2211-9140 https://doi.org/10.23876/j.krcp.2018.37.2.167 KIDNEY RESEARCH AND CLINICAL PRACTICE Long-term prognosis of BK

More information

CURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961

CURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961 CURRICULUM VITAE July 5, 2014 Name Chang-Kwon Oh Date of Birth August 15, 1961 Present Academic & Hospital Appointment Professor, Department of Surgery Ajou University, School of Medicine Chief, Department

More information

Management of a Recipient with a Failed Kidney Transplant. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania

Management of a Recipient with a Failed Kidney Transplant. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Management of a Recipient with a Failed Kidney Transplant Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Disclosures Grant support: Bristol-Myers and Squibb Pharmaceuticals,

More information

Antibody Mediated Rejection in Heart Transplantation

Antibody Mediated Rejection in Heart Transplantation Antibody Mediated Rejection in Heart Transplantation 2012 Teresa De Marco, MD, FACC Professor of Medicine & Surgery Director Heart Failure and Pulmonary Hypertension Program Medical Director, Heart Transplantation

More information

Health technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study:

Health technology Two prophylaxis schemes against organ rejection in renal transplantation were compared in the study: An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation Polsky D, Weinfurt K P, Kaplan B, Kim J, Fastenau J, Schulman K A Record Status

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding

More information

Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy

Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy Kidney International, Vol. 65 (2004), pp. 2409 2418 Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy YVO W. SIJPKENS,SIMONE A. JOOSTEN,MAN-CHI WONG, FRIEDO W. DEKKER,

More information

Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis

Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis Significance of Basiliximab Induction Therapy in Standard-Risk Renal Transplant in Tacrolimus Era: A Meta-Analysis Hatem Ali 1,2, Atif Mohiuddin 2,3, Ajay Sharma 2,3, Mohsen El Kosi 2,4 and Ahmed Halawa

More information

Induction of donor-specific hyporesponsiveness after renal. transplantation. Long term follow-up

Induction of donor-specific hyporesponsiveness after renal. transplantation. Long term follow-up Induction of donor-specific hyporesponsiveness after renal transplantation. Long term follow-up Marc Lúcia, Oriol Bestard, Marcel la Franquesa, Josep M Cruzado, Montse Gomà, Núria Bolaños, Gema Cerezo,

More information

C4d Fixing, Luminex Binding Antibodies A New Tool for Prediction of Graft Failure After Heart Transplantation

C4d Fixing, Luminex Binding Antibodies A New Tool for Prediction of Graft Failure After Heart Transplantation American Journal of Transplantation 27; 7: 289 2815 Blackwell Munksgaard Brief Communication C 27 The Authors Journal compilation C 27 The American Society of Transplantation and the American Society of

More information

J Am Soc Nephrol 13: , 2002

J Am Soc Nephrol 13: , 2002 J Am Soc Nephrol 13: 2371 2380, 2002 Capillary Deposition of Complement Split Product C4d in Renal Allografts is Associated with Basement Membrane Injury in Peritubular and Glomerular Capillaries: A Contribution

More information

THERAPEUTIC PLASMA EXCHANGE

THERAPEUTIC PLASMA EXCHANGE THERAPEUTIC PLASMA EXCHANGE DIRECTORATE OF NEPHROLOGY AND TRANSPLANTATION Background and Indications Therapeutic plasma exchange (TPE) is an extracorporeal blood purification technique in which plasma

More information

Intravenous immunoglobulin in BK virus nephropathy

Intravenous immunoglobulin in BK virus nephropathy Washington University School of Medicine Digital Commons@Becker Open Access Publications 2014 Intravenous immunoglobulin in BK virus nephropathy Elizabeth I. Anyaegbu Driscoll Children's Hospital Stanley

More information

Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts

Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts Peter Liptak and Bela Ivanyi* SUMMARY Calcineurin inhibitors (ciclosporin and tacrolimus) can cause acute and chronic nephrotoxicity.

More information